Publications by authors named "Bradley D Vince"
Article Synopsis
- Serdexmethylphenidate (SDX) chloride is a new prodrug of d-methylphenidate (d-MPH) being evaluated for its potential for abuse in recreational drug users through various administration methods (oral, intranasal, intravenous).
- Studies showed that subjective measures of drug liking (E) were significantly higher for d-MPH compared to SDX, indicating d-MPH has a greater potential for abuse regardless of how it’s taken.
- Overall, the results suggest SDX has a lower abuse potential than d-MPH, supporting its classification as a C-IV controlled substance.
Objective: Arhalofenate (ARH), in development for gout, has uricosuric and anti-flare activities. ARH plus febuxostat (FBX) were evaluated in subjects with gout for serum uric acid (SUA) lowering, drug interaction, and safety.
Methods: Open phase II trial in gout volunteers (NCT02252835).
The effects of steady-state faldaprevir on the safety, pharmacokinetics, and pharmacodynamics of steady-state methadone and buprenorphine-naloxone were assessed in 34 healthy male and female subjects receiving stable addiction management therapy. Subjects continued receiving a stable oral dose of either methadone (up to a maximum dose of 180 mg per day) or buprenorphine-naloxone (up to a maximum dose of 24 mg-6 mg per day) and also received oral faldaprevir (240 mg) once daily (QD) for 8 days following a 480-mg loading dose. Serial blood samples were taken for pharmacokinetic analysis.
View Article and Find Full Text PDFThe safety and efficacy of guanfacine extended release (up to 4 mg/day) for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6-17 years is well documented. Data suggest that weight-adjusted doses of guanfacine extended release >0.08 mg/kg but ≤0.
View Article and Find Full Text PDFArticle Synopsis
- This study aimed to evaluate whether guanfacine extended release (GXR) affects psychomotor functioning, alertness, and daytime sleepiness in young individuals with ADHD.
- Conducted on 182 subjects aged 6 to 17, the study found no significant differences in alertness or psychomotor performance between GXR and placebo groups, though some mild to moderate sedation was reported during dosage changes.
- Results indicated that GXR significantly improved ADHD symptoms without increasing daytime sleepiness, suggesting its efficacy as a treatment option.